Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Earnings & Valuation
This table compares Bio-Rad Laboratories and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 3.89 | $759.90 million | $8.25 | 45.61 |
| Ginkgo Bioworks | $170.15 million | 3.17 | -$312.76 million | ($5.01) | -1.60 |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and Ginkgo Bioworks, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
Bio-Rad Laboratories presently has a consensus target price of $343.33, indicating a potential downside of 8.75%. Ginkgo Bioworks has a consensus target price of $6.33, indicating a potential downside of 20.93%. Given Bio-Rad Laboratories’ stronger consensus rating and higher probable upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Ginkgo Bioworks.
Profitability
This table compares Bio-Rad Laboratories and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 8.59% | 3.54% | 2.48% |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
Insider & Institutional Ownership
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Bio-Rad Laboratories has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Summary
Bio-Rad Laboratories beats Ginkgo Bioworks on 12 of the 14 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
